{"title":"生物治疗难治性 RA","authors":"Jessica McHugh","doi":"10.1038/s41584-024-01132-6","DOIUrl":null,"url":null,"abstract":"The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.","PeriodicalId":18810,"journal":{"name":"Nature Reviews Rheumatology","volume":"20 7","pages":"395-395"},"PeriodicalIF":29.4000,"publicationDate":"2024-06-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"BiTEing refractory RA\",\"authors\":\"Jessica McHugh\",\"doi\":\"10.1038/s41584-024-01132-6\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.\",\"PeriodicalId\":18810,\"journal\":{\"name\":\"Nature Reviews Rheumatology\",\"volume\":\"20 7\",\"pages\":\"395-395\"},\"PeriodicalIF\":29.4000,\"publicationDate\":\"2024-06-10\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Reviews Rheumatology\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://www.nature.com/articles/s41584-024-01132-6\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"RHEUMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Reviews Rheumatology","FirstCategoryId":"3","ListUrlMain":"https://www.nature.com/articles/s41584-024-01132-6","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"RHEUMATOLOGY","Score":null,"Total":0}
The bispecific T cell engager (BiTE) blinatumomab showed promising clinical efficacy in a pilot study of six patients with multidrug-resistant rheumatoid arthritis.
期刊介绍：
Nature Reviews Rheumatology is part of the Nature Reviews portfolio of journals. The journal scope covers the entire spectrum of rheumatology research. We ensure that our articles are accessible to the widest possible audience.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
